Gene and protein expression profiling during differentiation of neuroblastoma cells triggered by 13-cis retinoic acid

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 9, 2003, Pages 715-720

  Yuza, Yuki ^a   Agawa, Miyuki ^a   Matsuzaki, Masaharu ^b   Yamada, Hisashi ^a   Urashima, Mitsuyoshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BD Biosciences Clontech   (Japan)

Author keywords

Cis retinoic acid; Differentiation; Isotretinoin; Neuroblastoma; Oligodeoxyribonucleotide array sequence analysis; Protein array assay; Retinoblastoma protein

Indexed keywords

CYCLIN D3; DNA; GENE PRODUCT; ISOTRETINOIN; PROTEIN C MYB; PROTEIN DP 1; PROTEIN P107; PROTEIN P130; PROTEIN P300; RETINOBLASTOMA PROTEIN; RNA; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; WNT PROTEIN; WNT10B PROTEIN;

ARTICLE; DISEASE ASSOCIATION; DNA FINGERPRINTING; DNA MICROARRAY; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTRETINOIN; NEOPLASM PROTEINS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0041733657     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200309000-00008     Document Type: Article

References (46)

1. Nishihira H, Toyoda Y, Tanaka Y, et al. Natural course of neuroblastoma detected by mass screening: a 5-year prospective study at a single institution. J Clin Oncol. 2000;18:3012-3017.
2. Fulda S, Lutz W, Schwab M, et al. MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med Pediatr Oncol. 2000;35:582-584.
3. Cotterill SJ, Pearson AD, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group Survey 1982-1992. Eur J Cancer. 2000;36:901-908.
4. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. 131 I-metaiodobenzyl-guanidine (131 I-MIBG) therapy for residual neuroblastoma: a monoinstitutional experience with 43 patients. Br J Cancer. 1999;81:1378-1384.
5. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer. 2001;84:460-464.
6. Pession A, Prete A, Locatelli F, et al. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer. 1998;78:528-533.
7. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-Cis retinoic acid. N Engl J Med. 1999;341:1165-1173.
8. Kohler JA, Imeson J, Ellershaw C, et al. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer. 2000;83:1124-1127.
9. Sidell N, Altman A, Haussler MR, et al. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res. 1983;148:21-30.
10. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc preceded retinoic acid - induced morphological differentiation of human neuroblastoma. Nature. 1985;313:404-406.
11. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
12. Giannini G, Kim CJ, Marcotullio LD, et al. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br J Cancer. 2000;83:1503-1509.
13. Peaston AE, Gardaneh M, Franco AV, et al. MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer. 2001;85:1564-1571.
14. Perel Y, Amrein L, Dobremez E, et al. Galanin and galanin receptor expression neuroblastic tumours: correlation with their differentiation status. Br J Cancer. 2002;86:117-122.
15. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous coculture. Cancer Res. 1973;33:2643-2652.
16. Schlesinger HR, Gerson JM, Moorhead PS, et al. Establishment and characterization of human neuroblastoma cell lines. Cancer Res. 1976;36:3094-3100.
17. Khan AA, Villablanca JG. Pharmacokinetic studies of 13-Cis retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol. 1996;39:34-41.
18. Villablanca JG, Khan AA, Avramis VI, et al. Phase I trial of 13-Cis retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995;13:894-901.
19. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
20. Nakamura M, Matsuo T, Stauffer J, et al. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ. 2003;10:230-239.
21. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev. 2002;16:2699-2712.
22. Sadee W, Yu VC, Richards ML, et al. Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. Cancer Res. 1987;47:5207-5212.
23. El Yazidi-Belkoura I, Adriaenssens E, Dolle L, et al. Tumor necrosis factor receptor-associated death domain protein (TRADD) is involved in the neurotrophin receptor (p75NTR)-mediated anti-apoptotic activity of nerve growth factor in breast cancer cells. J Biol Chem. 2003;Feb:25.
24. Kirikoshi H, Katoh M. Expression and regulation of WNT10B in human cancer: up-regulation of WNT10B in MCF-7 cells by beta-estradiol and down-regulation of WNT10B in NT2 cells by retinoic acid. Int J Mol Med. 2002;10:507-511.
25. Kurihara S, Hakuno F, Takahashi S. Insulin-like growth factor-1-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway. Endocrin J. 2000;47:739-751.
26. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci. 2000;57:1613-1636.
27. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756-760.
28. Ekman N, Arighi E, Rajantie I, et al. The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene. 2000;19:4151-4158.
29. Holland P, Willis C, Kanaly S, et al. RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation. Curr Biol. 2002;12:1424-1428.
30. Munz B, Hildt E, Springer ML, et al. RIP2, a checkpoint in myogenic differentiation. Mol Cell Biol. 2002;22:5879-5886.
31. Weinberg R. The retinoblastoma protein and cell cycle control. Cell. 1995;81:322-330.
32. Morris L, Allen KE, La Thangue NB. Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators. Nat Cell Biol. 2000;2:232-239.
33. Kranenburg O, Scharnhorst V, Van der Eb AJ, et al. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol. 1995;131:227-234.
34. Kim Ta. Lim J, Ota S, et al. NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation. J Cell Biol. 1998;141:553-566.
35. Raschella G, Tanno B, Bonetto F, et al. The RB-related gene RB2/p130 in neuroblastoma differentiation and in B-myb promoter down-regulation. Cell Death Diff. 1998;5:401-407.
36. Jori FP, GAlderishi U, Piegari E, et al. RB2/p130 ectopic gene expression in neuroblastoma stem cells: evidence of cell-fate restriction and induction of differentiation. Biochem J. 2001;360:569-577.
37. Tanno B, Bonetto F, Negroni A, et al. Retinoblastoma family proteins include differentiation and regulate B-myb expression in neuroblastoma cells. Med Pediatr Oncol. 2001;36:104-107.
38. Laiho M, DeCaprio JA, Ludlow JW, et al. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell. 1990;62:175-185.
39. Reed JC, Meister L, Tanaka S, et al. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. 1991;51:6529-6538.
40. Wagner N, Wagner KD, Schley G, et al. The Wilms' tumor suppressor Wtl is associated with the differentiation of retinoblastoma cells. Cell Growth Differ. 2002;13:297-305.
41. Redies C, Takeichi M. N- and R-cadherin expression in the optic nerve of the chicken embryo. Glia. 1993;8(3):161-171.
42. Satoh J, Kuroda Y. Beta-catenin expression in human neural cell lines following exposure to cytokines and growth factors. Neuropathology. 2000;20:113-123.
43. Lee MW, Park SC, Chae HS, et al. The protective role of HSP90 against 3-hydroxykynurenine-induced neuronal apoptosis. Biochem Biophys Res Commun. 2001;284:261-267.
44. Greenwood JA, Scott CW, Spreen RC, et al. Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine 39 as the primary phosphate acceptor. J Biol Chem. 1994;269:4373-4380.
45. Avila J, Ulloa L, Gonzalez J, et al. Phosphorylation of microtubule-associated proteins by protein kinase CK2 in neuritogenesis. Cell Mol Biol Res. 1994;405:573-579.
46. β2 expression in SK-N-BE2(c) neuroblastoma cells and regulate a differentiation-apoptosis switch. Mol Cell Biol. 1998;18:6482-6492.